Q.01

What is a Notice of Compliance from Health Canada?

A Notice of Compliance (NOC) is Health Canada's formal marketing authorization for a new drug. Health Canada's NOC page defines it as "a notification, issued pursuant to paragraph C.08.004(1)(a), indicating that a manufacturer has complied with sections C.08.002 or C.08.003 and C.08.005.1 of the Food and Drug Regulations." It is issued to the manufacturer after a satisfactory review of its submission, once the product meets Health Canada's requirements for safety, efficacy and quality (Health Canada, Notice of Compliance).

Approach: I used Health Canada's NOC page, its Notice of Compliance database and its drug guidance documents.

How it works

  • Which submissions get one: NOCs are issued on drug submissions. These include New Drug Submissions (NDS), Supplements to a New Drug Submission (SNDS), and Abbreviated New Drug Submissions (ANDS) for generics. An ANDS is compared against a "Canadian reference product," which the Regulations define as a drug "in respect of which a notice of compliance is issued pursuant to section C.08.004" and marketed in Canada by the innovator [1].
  • New indications also get one: For example, Novo Nordisk received an NOC on an SNDS, under priority review, for Wegovy (semaglutide injection). It covers non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (stages F2 to F3) [2]. The first semaglutide NOC was issued on an NDS [3].
  • Changes after approval: Changes to a drug that already holds an NOC under section C.08.004 are handled under Health Canada's Post-NOC Changes guidance framework [4][5].

NOC with Conditions (NOC/c) This is "a Notice of Compliance that is issued with a notation relating to a Letter of Undertaking." It may be granted when:

  • the drug shows promising clinical benefit;
  • it has an acceptable safety profile based on a benefit/risk assessment; and
  • it is of high quality.

It applies to serious, life-threatening or severely debilitating diseases or conditions. Before authorization, the sponsor "must" submit a Letter of Undertaking that commits it to confirmatory trials and enhanced post-market monitoring. The NOC/c designation applies to the specific indication, not to the product as a whole [1]. In Health Canada's NOC listings, these products carry the note "issued under the NOC/c policy" after the brand name (Health Canada, Notice of Compliance).

Where to find NOCs Health Canada publishes them in its searchable NOC database and in its NOC listings.

Q.02

How do NDS, ANDS and SNDS submissions differ?

The three submission types differ by what the drug is and what evidence supports it. An NDS is the full submission for a new drug, carrying the sponsor's own safety and efficacy data. An ANDS is the generic route: it relies on showing pharmaceutical equivalence and bioequivalence to a Canadian reference product (CRP). An SNDS is a supplement filed later to change a drug that already holds a Notice of Compliance (NOC). All three can lead to an NOC.

Approach: I used Health Canada's drug guidance documents. These cover NOC with Conditions, Quality (Chemistry and Manufacturing), biosimilars, third-party data, the Patented Medicines (NOC) Regulations, labelling and GMP filing requirements. I did not open the Food and Drug Regulations themselves, so the section numbers below come from how Health Canada cites them in that guidance.

NDSANDSSNDS
Section of the Food and Drug RegulationsC.08.002C.08.002.1C.08.003
Used forA new drug. Biosimilars also use this route, under C.08.002 [6]A generic (subsequent-entry) version of an innovator productChanges to a drug that already has an NOC (for example a new indication, formulation, strength, dosage form or labelling)
Core evidenceDetailed safety reports, among other items. Content is set by C.08.002(2), including (g) "detailed reports of the tests made to establish the safety of the new drug" [7]Pharmaceutical equivalence and bioequivalence against the CRP. The manufacturer "must meet" these requirements to file [8]Data covering the proposed change. Content is set by C.08.003(3) [7]

NDS (New Drug Submission)

  • An NDS can rely heavily on published literature and market experience instead of the sponsor's own trials. In that case the sponsor is "required to provide evidence" that those data match the proposed use in dosing, population, intervention and outcome measures. The same applies to an SNDS [7].
  • Biosimilars cannot use the ANDS route "due to their inherent heterogeneity and complexity", so they are filed as an NDS [6].

ANDS (Abbreviated New Drug Submission)

  • Comparing against the CRP is meant to show that the generic's safety and efficacy will match the innovator product, which is marketed in Canada and whose safety and efficacy were shown clinically. A reference product sourced from outside Canada can serve as the CRP if the Minister accepts it [8].
  • A chemically synthesized version of a biologic may be eligible for the ANDS route, decided case by case [6].

SNDS (Supplement to a New Drug Submission)

  • Health Canada calls the supplement route S(A)NDS because generics have a parallel version, the SANDS. It covers new dosage forms, new strengths and "other changes to authorized products" [9].
  • Changes made only to label design are filed as "S(A)NDS Labelling Only" for Division 8 drugs [10].
  • If a supplement changes the labels, C.08.003(3.1) says it "shall contain" mock-ups of every label [11].
  • The Wegovy MASH approval from my last answer is an example of an SNDS for a new indication [2].

Where the three routes are treated differently

  • Patent listing: Only an NDS, or an SNDS for a change in formulation, dosage form or use of the medicinal ingredient, can add a patent to the Patent Register. A newly listed patent must claim the change that was approved [12].
  • NOC with Conditions (NOC/c):
    • An NDS or SNDS qualifies on its own merits. The sponsor "must undertake" to run confirmatory trials.
    • An ANDS or SANDS falls under NOC/c only when its CRP still holds NOC/c status. Confirmatory trials are then required only "if deemed necessary."
    • Once conditions are met, the innovator files an "SNDS-'c'" with the confirmatory results. The generic files a label-only "SANDS-'c'" to remove the conditions [1].
  • Requirements they share:
    • Every NDS, ANDS and supplement "shall contain" details of the method of manufacture and the manufacturing controls [13].
    • The same Quality (Chemistry and Manufacturing) guidance applies to both NDS and ANDS [9].
    • A proposed or changed brand name triggers a look-alike/sound-alike assessment for every (S)(A)NDS type [14].

Health Canada also has extraordinary-use versions of the first two routes: the extraordinary use NDS (EUNDS) and the abbreviated extraordinary use NDS (AEUNDS) [13].

Q.03

Does appearing on the submissions under review list mean approval?

No. Being on the Submissions Under Review (SUR) list means only that Health Canada has accepted the submission into review. It does not mean the drug is approved or will be. Approval comes only when a Notice of Compliance (NOC) is issued. Health Canada points users to the NOC database, not the SUR list, to find out whether a submission was approved (SUR overview; Generic SUR list).

Approach: I checked Health Canada's drug guidance documents and then read its SUR overview, the new-drug and generic lists, and the supplemental-completed list. The guidance only describes the list briefly, so the details below come from the SUR pages.

What the list contains

  • Scope: It covers new drug submissions containing new active substances, other new drug submissions, and supplemental new drug submissions for new uses (SUR overview). Generics are on a separate list, the Generic Submissions Under Review (GSUR) list, which covers ANDS.
  • When entries are added: Submissions are added "after they have been accepted into review." The lists are updated monthly (SUR overview; GSUR).
  • How Health Canada describes it: Its database listing calls the list a way to "identify substances accepted for review in Canada" [15].

What happens when the review ends

  • A submission moves from the under-review list to the completed list "when it reaches a conclusion (it is cancelled, or a final decision is made)" (SUR overview).
  • A generic is removed from the GSUR list when "the submission is cancelled or a final decision is made." It is not carried over to a completed list (GSUR).
  • The completed lists have a column headed "Outcome of submission." Outcomes recorded on the supplemental-completed list include (Supplemental submissions completed):
    • Issued Notice of Compliance
    • Issued Notice of Compliance under the NOC/c Guidance
    • Authorized under Interim Order
    • Cancelled by sponsor
    • Issued Notice of Non-compliance - Withdrawal (for example, a baricitinib submission concluded 2023-06-13)

A practical use of the list Health Canada's data protection guidance tells manufacturers they "are encouraged to consult the Submissions Under Review List" to see whether another submission for the same medicinal ingredient is under review. This matters because only the first drug issued an NOC can qualify for innovative drug data protection [16].

Q.04